Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery

被引:117
作者
Babiuk, S
Baca-Estrada, M
Babiuk, LA
Ewen, C
Foldvari, M
机构
[1] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
关键词
skin; transdermal; liposomes; vaccines; delivery;
D O I
10.1016/S0168-3659(99)00274-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Vaccination is one of the major achievements of modern medicine. As a result of vaccination, diseases such as polio and measles have been controlled and small pox has been eradicated. However, despite these successes there are still many microbial diseases that cause tremendous suffering because there is no vaccine or the vaccines available are inadequate. In addition, even if vaccines were available for all infectious diseases there is no guarantee that people would use them routinely. One of the major impediments to ensuring vaccine efficacy and compliance is that of delivery. Presently most vaccines are given by intramuscular administration. Unfortunately this is often traumatic, especially in infants. Thus, if it was possible to replace intramuscular immunization by mucosal (oral/intranasal) or transdermal delivery it may be possible to both enhance mucosal immunity as well as improve overall compliance rates. The transdermal route has been used by the pharmaceutical industry for the delivery of various low molecular weight drugs. Some of the approaches used for smaller compounds may also have potential for delivery of either protein or polynucleotide vaccines. However, there is a greater challenge to delivering large molecular weight molecules through the skin due to size, charge and other physicochemical properties. This review will describe the recent advances that have been made in dermal and topical delivery as related to vaccines. (C) 2000 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:199 / 214
页数:16
相关论文
共 137 条
  • [1] Adams S E, 1994, Int Rev Immunol, V11, P133, DOI 10.3109/08830189409061721
  • [2] Aggarwal N, 1999, CAN J VET RES, V63, P148
  • [3] DNA vaccines: Technology and application as anti-parasite and anti-microbial agents
    Alarcon, JB
    Waine, GW
    McManus, DP
    [J]. ADVANCES IN PARASITOLOGY, VOL 42, 1999, 42 : 343 - 410
  • [4] LIPOSOME-MEDIATED GENE-TRANSFER AND EXPRESSION VIA THE SKIN
    ALEXANDER, MY
    AKHURST, RJ
    [J]. HUMAN MOLECULAR GENETICS, 1995, 4 (12) : 2279 - 2285
  • [5] Comparison of numerous delivery systems for the induction of cytoxic T lymphocytes by immunization
    Allsopp, CEM
    Plebanski, M
    Gilbert, S
    Sinden, RE
    Harris, S
    Frankel, G
    Dougan, G
    Hioe, C
    Nixon, D
    Paoletti, E
    Layton, G
    Hill, AVS
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) : 1951 - 1959
  • [6] Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions
    Andrianov, AK
    Chen, JP
    Payne, LG
    [J]. BIOMATERIALS, 1998, 19 (1-3) : 109 - 115
  • [7] Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines
    Anwer, K
    Earle, KA
    Shi, M
    Wang, JJ
    Mumper, RJ
    Proctor, B
    Jansa, K
    Ledebur, HC
    Davis, S
    Eaglstein, W
    Rolland, AP
    Rolland, P
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (06) : 889 - 895
  • [8] Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12
    Baca-Estrada, ME
    Foldvari, M
    Snider, M
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (05) : 455 - 462
  • [9] Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D
    BacaEstrada, ME
    Foldvari, M
    Snider, M
    LittelvandenHurk, SV
    Babiuk, LA
    [J]. VACCINE, 1997, 15 (16) : 1753 - 1760
  • [10] Neutralizing antiviral B cell responses
    Bachmann, MF
    Zinkernagel, RM
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 235 - 270